Literature DB >> 24419569

Cardiovascular complications in atypical haemolytic uraemic syndrome.

Marina Noris1, Giuseppe Remuzzi2.   

Abstract

Haemolytic uraemic syndrome (HUS) is characterized by nonimmune haemolytic anaemia, thrombocytopenia and renal impairment-most incidents in childhood are caused by shiga toxin-producing bacteria. Atypical HUS (aHUS) accounts for 10% of cases and has a poor prognosis. About 60% of patients with aHUS have dysregulation of the alternative complement pathway (complement-mediated aHUS). The kidney is the main target organ, but other organs might also be affected. Cardiac complications occur in 3-10% of patients with complement-mediated aHUS, as a consequence of microangiopathic injury in the coronary microvasculature, and can cause sudden death. Emerging evidence also suggests that either thrombosis or stenosis of the medium and large arteries might complicate disease course, and such disorders occur even after renal function is lost. In this Perspectives article we discuss the impact of cardiovascular involvement in complement-mediated aHUS, the role of acute and chronic complement hyperactivation in such events and the implications for treatment.

Entities:  

Mesh:

Year:  2014        PMID: 24419569     DOI: 10.1038/nrneph.2013.280

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  69 in total

Review 1.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

2.  A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome.

Authors:  Nigel J Francis; Bairbre McNicholas; Atif Awan; Mary Waldron; Donal Reddan; Denise Sadlier; David Kavanagh; Lisa Strain; Kevin J Marchbank; Claire L Harris; Timothy H J Goodship
Journal:  Blood       Date:  2011-11-04       Impact factor: 22.113

Review 3.  Thrombotic thrombocytopenic purpura--then and now.

Authors:  Miriam Galbusera; Marina Noris; Giuseppe Remuzzi
Journal:  Semin Thromb Hemost       Date:  2006-03       Impact factor: 4.180

4.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

Review 5.  The role of the host defense system in the development of cerebral vasospasm: analogies between atherosclerosis and subarachnoid hemorrhage.

Authors:  Hiroji Yanamoto; Hiroharu Kataoka; Yukako Nakajo; Koji Iihara
Journal:  Eur Neurol       Date:  2012-10-24       Impact factor: 1.710

Review 6.  The role of complement in atherosclerosis.

Authors:  Dorian O Haskard; Joseph J Boyle; Justin C Mason
Journal:  Curr Opin Lipidol       Date:  2008-10       Impact factor: 4.776

7.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

Review 8.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

9.  Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.

Authors:  Jean-Claude Davin; Valentina Gracchi; Antonia Bouts; Jaap Groothoff; Lisa Strain; Tim Goodship
Journal:  Am J Kidney Dis       Date:  2009-10-25       Impact factor: 8.860

10.  Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome.

Authors:  David Kavanagh; Anna Richards; Marina Noris; Richard Hauhart; M Kathryn Liszewski; Diana Karpman; Judith A Goodship; Veronique Fremeaux-Bacchi; Giuseppe Remuzzi; Timothy H J Goodship; John P Atkinson
Journal:  Mol Immunol       Date:  2007-06-26       Impact factor: 4.407

View more
  21 in total

Review 1.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

2.  Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome.

Authors:  Shruti Chaturvedi; Noor Dhaliwal; Sarah Hussain; Kathryn Dane; Harshvardhan Upreti; Evan M Braunstein; Xuan Yuan; C John Sperati; Alison R Moliterno; Robert A Brodsky
Journal:  Blood Adv       Date:  2021-03-09

3.  Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab.

Authors:  Khadizha Emirova; Elena Volokhina; Evgenia Tolstova; Bert van den Heuvel
Journal:  BMJ Case Rep       Date:  2016-02-15

4.  Extra-Renal manifestations of atypical hemolytic uremic syndrome in children.

Authors:  Kibriya Fidan; Nilüfer Göknar; Bora Gülhan; Engin Melek; Zeynep Y Yıldırım; Esra Baskın; Mutlu Hayran; Kaan Gülleroglu; Zeynep B Özçakar; Fatih Ozaltin; Oguz Soylemezoglu
Journal:  Pediatr Nephrol       Date:  2018-04-02       Impact factor: 3.714

Review 5.  Extra-renal manifestations of atypical hemolytic uremic syndrome.

Authors:  Cassandra Formeck; Agnieszka Swiatecka-Urban
Journal:  Pediatr Nephrol       Date:  2018-08-14       Impact factor: 3.714

6.  Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy: first report from iran.

Authors:  Mohammadreza Ardalan; Parisa Rezaeifar
Journal:  Nephrourol Mon       Date:  2014-11-11

Review 7.  Extra-renal manifestations of complement-mediated thrombotic microangiopathies.

Authors:  Johannes Hofer; Alejandra Rosales; Caroline Fischer; Thomas Giner
Journal:  Front Pediatr       Date:  2014-09-08       Impact factor: 3.418

8.  Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.

Authors:  ChongTing Lin; Qing Zhang; HuiFang Zhang; AiXia Lin
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-07-30       Impact factor: 3.738

9.  Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome.

Authors:  John L Vaughn; Jared M Moore; Spero R Cataland
Journal:  Case Rep Hematol       Date:  2015-10-18

10.  The global aHUS registry: methodology and initial patient characteristics.

Authors:  Christoph Licht; Gianluigi Ardissino; Gema Ariceta; David Cohen; J Alexander Cole; Christoph Gasteyger; Larry A Greenbaum; Sally Johnson; Masayo Ogawa; Franz Schaefer; Johan Vande Walle; Véronique Frémeaux-Bacchi
Journal:  BMC Nephrol       Date:  2015-12-10       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.